Diabetic peripheral neuropathy (DPN) is the most common late complication of diabetes mellitus and the single strongest predictor of diabetic foot ulceration, since loss of protective sensation removes the early warning system that normally alerts a person to minor trauma. Because DPN often progresses silently before symptoms are noticed, understanding how it is detected and how treatment approaches are evolving has direct clinical relevance for anyone involved in diabetes-related foot care.
Why Early Detection Matters
Neuropathic pain affects an estimated 30% to 50% of people living with DPN, but a substantial share of patients have little or no symptoms despite significant sensory loss (Røikjer et al., 2024). This asymptomatic subgroup is particularly important clinically, because the absence of pain does not indicate the absence of risk. A multidisciplinary expert panel writing in Frontiers in Endocrinology emphasized that clinician suspicion is often the limiting factor in diagnosis, noting that DPN remains substantially underrecognized in routine practice (Atmaca et al., 2024). The panel’s proposed approach begins with a focused history for neuropathic symptoms and risk factors—including age over 50, obesity, hypertension, dyslipidemia, and suboptimal glycemic control—followed by a structured bedside examination.
Screening Tools in Current Use
No single bedside test provides a gold-standard diagnosis of DPN, so current guidance favors a combination of assessments. The 2023 update of the International Working Group on the Diabetes-related Foot (IWGDF) guidelines continues to recommend the 10-gram monofilament together with at least one additional test—such as vibration perception with a 128 Hz tuning fork, pinprick sensation, or ankle reflexes—to stratify a patient’s risk of ulceration (Bus et al., 2024). The Frontiers in Endocrinology expert panel outlined a similar composite bedside protocol: 128 Hz tuning fork for vibration sense, neurotips or a cold tuning fork for small-fiber function, 1g and 10g monofilaments for pressure sensation, light touch with a cotton wisp, and ankle and patellar reflex testing, combined with visual inspection for deformity or ulceration (Atmaca et al., 2024).
Where access to multiple instruments is limited, a review in Diabetology & Metabolic Syndrome evaluated adjunct tools, including the Michigan Neuropathy Screening Instrument, the Neuropad point-of-care indicator test, and the Ipswich Touch Test as a practical substitute for monofilament testing (Nkonge et al., 2023). The authors concluded that combining a validated screening instrument with a point-of-care test increases sensitivity and specificity compared with any single test used alone.
Emerging Diagnostic Methods
Beyond bedside testing, several objective methods are being studied to detect nerve damage earlier and track its progression. These include skin biopsy for intraepidermal nerve fiber density, corneal confocal microscopy to visualize small-fiber damage noninvasively, nerve excitability testing for subclinical axonal dysfunction, and blood-based biomarkers such as neurofilament light chain (Røikjer et al., 2024). None has yet replaced standard bedside screening in routine practice, but each is increasingly used in research and specialty settings to characterize neuropathy severity over time.
Management: Glycemic Control, Disease-Modifying Therapy, and Symptom Control
Management of DPN operates on two separate tracks: slowing nerve damage and controlling symptoms. Intensive glycemic control remains the most consistently supported intervention for reducing incident neuropathy, with a more pronounced effect demonstrated in type 1 diabetes than in type 2 diabetes, alongside broader multifactorial risk reduction addressing blood pressure, lipids, and weight (Atmaca et al., 2024). Among pathogenesis-directed therapies, alpha-lipoic acid has the most established evidence base, with trial data supporting oral dosing of 600 mg daily for improving symptom scores and nerve conduction parameters, and observational data suggesting sustained benefit over several years (Atmaca et al., 2024).
For neuropathic pain itself, the panel noted that available pharmacologic options provide adequate relief in fewer than one-third of patients, underscoring a persistent treatment gap (Atmaca et al., 2024). This has driven interest in mechanistic approaches under investigation, including selective sodium-channel blockers targeting Nav1.7, Nav1.8, and Nav1.9 subtypes in sensory neurons, calcitonin gene-related peptide (CGRP) antibodies already approved for migraine and now being trialed for painful DPN, low-dose naltrexone, and spinal cord stimulation, which has shown durable relief in trial cohorts using newer high-frequency protocols (Røikjer et al., 2024). No disease-modifying agent has yet been established that reverses established nerve damage, which keeps prevention and early detection central to clinical management.
Clinical Summary
Diabetic peripheral neuropathy remains underdiagnosed relative to its prevalence, and its silent progression makes structured, combination-based bedside screening—rather than reliance on symptom report alone—essential to identifying at-risk feet before ulceration occurs. Current guideline-supported screening combines the 10g monofilament with a second modality such as vibration or reflex testing, while alpha-lipoic acid and intensive glycemic control remain the most established options for slowing disease progression. Pain management remains only partially effective with existing agents, and a pipeline of mechanism-targeted therapies and objective diagnostic biomarkers is under investigation but has not yet reached routine practice.
References
Atmaca A, Ketenci A, Sindel M, et al. Expert opinion on screening, diagnosis and management of diabetic peripheral neuropathy: a multidisciplinary approach. Frontiers in Endocrinology. 2024;15:1380929.
Røikjer J, Kristensen AG, Karlsson P. Diabetic Peripheral Neuropathy: Emerging Treatments of Neuropathic Pain and Novel Diagnostic Methods. Journal of Diabetes Science and Technology. 2024.
Nkonge TN, Nkonge KM, Nkonge DK. Screening for diabetic peripheral neuropathy in resource-limited settings. Diabetology & Metabolic Syndrome. 2023;15:11.
Bus SA, Lipsky BA, Armstrong DG, et al. Guidelines on the prevention of foot ulcers in persons with diabetes (IWGDF 2023 update). Diabetes/Metabolism Research and Reviews. 2024;40(3):e3651.
Comments
